MedPath

FDA Grants Cancer Drug Approvals to AbbVie and MSD, AbbVie Announces $335M ADARx Partnership

• The FDA has approved new cancer therapeutics from AbbVie and MSD, expanding treatment options for specific oncology indications.

• AbbVie has simultaneously announced a strategic collaboration with ADARx Pharmaceuticals, committing $335 million upfront to access ADARx's siRNA platform technology.

• The partnership aims to combine expertise in RNA technologies, antibody-drug conjugates (ADCs), and targeted delivery systems to accelerate development of novel cancer therapeutics.

The U.S. Food and Drug Administration (FDA) has granted approvals for new cancer therapeutics from pharmaceutical giants AbbVie and MSD (known as Merck & Co. in the U.S. and Canada), marking significant advancements in oncology treatment options.
AbbVie received approval for Emrelis, while the specific details of MSD's approved therapy were not disclosed in the available information. These approvals represent important additions to the companies' oncology portfolios and provide new treatment avenues for cancer patients.

AbbVie's Dual Announcement: Drug Approval and Strategic Partnership

In a notable development for AbbVie, the FDA approval of Emrelis coincided with the company's announcement of a major strategic collaboration with ADARx Pharmaceuticals. AbbVie has committed $335 million upfront to access ADARx's small interfering RNA (siRNA) platform technology.
The substantial investment underscores AbbVie's confidence in the potential of RNA-based therapeutics for cancer treatment. According to the announcement, the partnership aims to leverage complementary expertise from both companies in RNA technologies, antibody-drug conjugates (ADCs), and targeted delivery systems.

Strategic Implications of the ADARx Collaboration

This collaboration represents a significant strategic move for AbbVie as it continues to strengthen its position in the competitive oncology market. The siRNA platform from ADARx offers promising capabilities for silencing disease-causing genes, potentially enabling more precise targeting of cancer cells while minimizing damage to healthy tissue.
Industry analysts view this partnership as part of a broader trend of major pharmaceutical companies investing in RNA-based therapeutic approaches, which have shown increasing promise in recent years for treating previously undruggable targets.

Expanding Oncology Portfolios

The FDA approvals for both AbbVie and MSD add to their growing oncology portfolios. These companies have been increasingly focusing on cancer therapeutics as a key growth area, given the significant unmet medical needs that remain across various cancer types.
For AbbVie, the approval of Emrelis provides an important new revenue stream as the company continues to diversify beyond its blockbuster immunology drug Humira, which has faced biosimilar competition in recent years.

Market Impact and Future Directions

The dual announcements from AbbVie—FDA approval and the ADARx partnership—signal the company's commitment to innovation in cancer treatment through both near-term product launches and long-term research investments.
The financial markets will likely be watching closely to see how these developments impact AbbVie's competitive position in oncology, particularly as the company works to offset revenue challenges from Humira's patent expiration.
For patients and healthcare providers, these approvals represent potentially valuable new options in the cancer treatment landscape, though the full clinical impact will depend on the specific indications, efficacy profiles, and accessibility of these newly approved therapies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

AbbVie and ADARx Form $335 Million Collaboration to Develop Next-Generation siRNA Therapies

AbbVie has invested $335 million upfront in a strategic collaboration with ADARx Pharmaceuticals to develop small interfering RNA therapeutics across neuroscience, immunology, and oncology.
The partnership combines ADARx's proprietary RNA technology for precise mRNA silencing with AbbVie's expertise in antibody engineering, ADCs, and tissue delivery approaches to overcome siRNA targeting challenges.

FDA Approves Subcutaneous Opdivo Qvantig for Multiple Solid Tumors

The FDA approved Opdivo Qvantig, a subcutaneous injection of nivolumab, for adult solid tumors previously approved for intravenous Opdivo.
CheckMate-67T trial data showed non-inferior pharmacokinetic exposures, similar efficacy, and comparable safety to intravenous Opdivo.

uniQure Receives FDA Nod for Accelerated Approval Pathway for Huntington's Disease Gene Therapy

uniQure secured FDA agreement to pursue accelerated approval for its Huntington's disease gene therapy, potentially expediting treatment availability.
The FDA's decision reflects a more flexible approach to genetic medicines for severe rare diseases under Peter Marks.

FDA Approves BridgeBio's Acoramidis (ATTRUBY) for Transthyretin Amyloid Cardiomyopathy

The FDA has approved acoramidis (ATTRUBY), an oral transthyretin stabilizer, for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, aiming to reduce cardiovascular death and hospitalization.
Approval was based on the Phase 3 ATTRibute-CM study, which demonstrated significant reductions in mortality and cardiovascular hospitalizations, along with improved patient quality of life.

Sanofi, RadioMedix, and Orano Med Partner to Develop Radioligand Therapy for Rare Cancers

Sanofi, RadioMedix, and Orano Med have entered an exclusive licensing agreement to develop AlphaMedix for rare cancers, focusing on neuroendocrine tumors (NETs).
AlphaMedix, a targeted alpha therapy, has received FDA Breakthrough Therapy Designation for gastroenteropancreatic NETs in patients treatment-naive to peptide-receptor radionuclide therapy.

AstraZeneca's Voydeya Approved for PNH, Merck Advances KRAS Inhibitor

The FDA has approved AstraZeneca's Voydeya (danicopan) as an add-on therapy for extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH).
Merck's oral KRAS G12C inhibitor candidate, MK-1084, has entered phase III development for first-line treatment of metastatic non-small cell lung cancer (NSCLC).

FDA Approves AstraZeneca and Ionis' Wainua for Hereditary ATTR Polyneuropathy

The FDA has approved AstraZeneca and Ionis' Wainua (eplontersen) for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Approval was based on the NEURO-TTRansform study, demonstrating Wainua's ability to improve neuropathy impairment and quality of life.

AbbVie to Acquire Cerevel, Novartis' Fabhalta Approved, and Other Pharma Updates

AbbVie is set to acquire Cerevel Therapeutics for $8.7 billion, bolstering its neuroscience pipeline with candidates targeting schizophrenia, Parkinson's disease, and mood disorders.
The FDA has approved Novartis' Fabhalta (iptacopan), the first oral monotherapy for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.

4DMedical, TrivarX, and Artrya Advance with FDA Clearances and US Partnerships

4DMedical's CT LVAS receives FDA clearance, expanding functional lung imaging accessibility in the US after its Australian rollout.
TrivarX accelerates its Phase 2 study for Major Depressive Episode, aiming to validate its MEB-001 algorithm for screening and diagnosis.

FDA Approves Bavencio: Merck KGaA and Pfizer's Breakthrough Immunotherapy for Rare Skin Cancer

The FDA has granted accelerated approval to Bavencio (avelumab), the first approved therapy for metastatic Merkel cell carcinoma, developed through Merck KGaA and Pfizer's collaboration.
Bavencio becomes the fourth checkpoint inhibitor to enter the market, joining established immunotherapies from Bristol-Myers Squibb, Merck & Co, and Roche in the oncology space.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy